Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis

Nature volume 413, pages 86–91 (2001)Cite this article

Abstract

The cyclin-dependent kinase inhibitor p16INK4a can induce senescence of human cells, and its loss by deletion, mutation or epigenetic silencing is among the most frequently observed molecular lesions in human cancer1,2. Overlapping reading frames in the INK4A/ARF gene encode p16INK4a and a distinct tumour-suppressor protein, p19ARF (ref. 3). Here we describe the generation and characterization of a p16Ink4a-specific knockout mouse that retains normal p19Arf function. Mice lacking p16Ink4a were born with the expected mendelian distribution and exhibited normal development except for thymic hyperplasia. T cells deficient in p16Ink4a exhibited enhanced mitogenic responsiveness, consistent with the established role of p16Ink4a in constraining cellular proliferation. In contrast to mouse embryo fibroblasts (MEFs) deficient in p19Arf (ref. 4), p16Ink4a-null MEFs possessed normal growth characteristics and remained susceptible to Ras-induced senescence. Compared with wild-type MEFs, p16Ink4a-null MEFs exhibited an increased rate of immortalization, although this rate was less than that observed previously for cells null for Ink4a/Arf, p19Arf or p53 (refs 4, 5). Furthermore, p16Ink4a deficiency was associated with an increased incidence of spontaneous and carcinogen-induced cancers. These data establish that p16Ink4a, along with p19Arf, functions as a tumour suppressor in mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Deletion of p16Ink4a.
Figure 2: Growth of p16Ink4a-null cells.
Figure 3: p16Ink4a-null mice are tumour prone.
Figure 4: Methylation of p16Ink4a in tumours.

Similar content being viewed by others

References

  1. Ruas, M. & Peters, G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378, F115–F177 (1998).

    CAS  PubMed  Google Scholar 

  2. Sharpless, N. E. & DePinho, R. A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 9, 22–30 (1999).

    Article  CAS  Google Scholar 

  3. Quelle, D. E., Zindy, F., Ashmun, R. A. & Sherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83, 993–1000 (1995).

    Article  CAS  Google Scholar 

  4. Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649–659 (1997).

    Article  CAS  Google Scholar 

  5. Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).

    Article  CAS  Google Scholar 

  6. Lakso, M. et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc. Natl Acad. Sci. USA 93, 5860–5865 (1996).

    Article  ADS  CAS  Google Scholar 

  7. Pham, C. T., MacIvor, D. M., Hug, B. A., Heusel, J. W. & Ley, T. J. Long-range disruption of gene expression by a selectable marker cassette. Proc. Natl Acad. Sci. USA 93, 13090–13095 (1996).

    Article  ADS  CAS  Google Scholar 

  8. Zindy, F., Quelle, D. E., Roussel, M. F. & Sherr, C. J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 15, 203–211 (1997).

    Article  CAS  Google Scholar 

  9. Alcorta, D. A. et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl Acad. Sci. USA 93, 13742–13747 (1996).

    Article  ADS  CAS  Google Scholar 

  10. Rogan, E. M. et al. Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol. Cell. Biol. 15, 4745–4753 (1995).

    Article  CAS  Google Scholar 

  11. Reznikoff, C. A. et al. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56, 2886–2890 (1996).

    CAS  PubMed  Google Scholar 

  12. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997).

    Article  CAS  Google Scholar 

  13. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).

    Article  ADS  CAS  Google Scholar 

  14. Carnero, A., Hudson, J. D., Price, C. M. & Beach, D. H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol. 2, 148–155 (2000).

    Article  CAS  Google Scholar 

  15. Dannenberg, J. H., van Rossum, A., Schuijff, L. & te Riele, H. Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev. 14, 3051–3064 (2000).

    Article  CAS  Google Scholar 

  16. Sage, J. et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14, 3037–3050 (2000).

    Article  CAS  Google Scholar 

  17. Groth, A., Weber, J. D., Willumsen, B. M., Sherr, C. J. & Roussel, M. F. Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J. Biol. Chem. 275, 27473–27480 (2000).

    CAS  PubMed  Google Scholar 

  18. Kamijo, T., Bodner, S., van de Kamp, E., Randle, D. H. & Sherr, C. J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59, 2217–2222 (1999).

    CAS  PubMed  Google Scholar 

  19. Zhang, S., Ramsay, E. S. & Mock, B. A. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. Proc. Natl Acad. Sci. USA 95, 2429–2434 (1998).

    Article  ADS  CAS  Google Scholar 

  20. Zhang, S. L. et al. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol. Cell. Biol. 21, 310–318 (2001).

    Article  Google Scholar 

  21. Linardopoulos, S. et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res. 55, 5168–5172 (1995).

    CAS  PubMed  Google Scholar 

  22. Swafford, D. S. et al. Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol. Cell. Biol. 17, 1366–1374 (1997).

    Article  CAS  Google Scholar 

  23. Herzog, C. R., Noh, S., Lantry, L. E., Guan, K. L. & You, M. Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis. Mol. Carcinog. 25, 92–98 (1999).

    Article  CAS  Google Scholar 

  24. Patel, A. C. et al. Hypermethylation of the p16 (Ink4a) promoter in B6C3F1 mouse primary lung adenocarcinomas and mouse lung cell lines. Carcinogenesis 21, 1691–1700 (2000).

    Article  CAS  Google Scholar 

  25. Buchmann, A., Ruggeri, B., Klein-Szanto, A. J. & Balmain, A. Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res. 51, 4097–4101 (1991).

    CAS  PubMed  Google Scholar 

  26. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821–9826 (1996).

    Article  ADS  CAS  Google Scholar 

  27. Herman, J. G. et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525–4530 (1995).

    CAS  PubMed  Google Scholar 

  28. Carrasco, D. et al. Multiple hemopoietic defects and lymphoid hyperplasia in mice lacking the transcriptional activation domain of the c-Rel protein. J. Exp. Med. 187, 973–984 (1998).

    Article  CAS  Google Scholar 

  29. Naviaux, R. K., Costanzi, E., Haas, M. & Verma, I. M. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70, 5701–5705 (1996).

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Matsushime, H. et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol. 14, 2066–2076 (1994).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank E. Farazi, S. Chan, M. Sinha, S. Alson and the Dana Farber Cancer Institute Mouse Core for experimental advice and assistance. We also thank H. Westphal, T. Devereux, M. Oren, M. Bosenberg, D. Silver and A. Buchmann for advice or reagents, and L. Chin, J. DeCaprio, W. Kaelin and P. Sicinski for comments on the manuscript. N.E.S. is an Howard Hughes Medical Institute Physician Postdoctoral Fellow; N.B. is supported by the American Cancer Society John Peter Hoffman Award; K.H.L. is supported by the National Nuclear R and D Program and Human Genome Program from the Korean Ministry of Science and Technology; D.H.C. is supported by a Physician Scientist Fellowship of the Damon Runyon–Walter Winchell Foundation; and R.A.D. is an American Cancer Society Professor and recipient of the Steven and Michele Kirsch Foundation Investigator Award. This work was supported by grants from the National Institutes of Health, the National Cancer Institute and the American Cancer Society.

Author information

Author notes

  1. Daniel Carrasco & Diego H. Castrillon

    Present address: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, 02115, Massachusetts, USA

  2. Kee-Ho Lee

    Present address: Laboratory of Molecular Oncology, Korea Cancer Center Hospital, Seoul, 139-706, Korea

Authors and Affiliations

  1. Departments of Adult Oncology, Medicine and Genetics, Harvard Medical School and the Dana-Farber Cancer Institute, Boston, 02115, Massachusetts, USA

    Norman E. Sharpless, Nabeel Bardeesy, Kee-Ho Lee, Daniel Carrasco, Diego H. Castrillon, Andrew J. Aguirre, Emily A. Wu, James W. Horner & Ronald A. DePinho

Authors
  1. Norman E. Sharpless
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nabeel Bardeesy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kee-Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diego H. Castrillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew J. Aguirre
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emily A. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. James W. Horner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ronald A. DePinho
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald A. DePinho.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sharpless, N., Bardeesy, N., Lee, KH. et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86–91 (2001). https://doi.org/10.1038/35092592

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/35092592

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing